+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Systemic Lupus Erythematosus Market: By Therapies, Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules & By Region - Forecast 2016-2021

  • ID: 3974168
  • Report
  • September 2016
  • Region: Global
  • 136 pages
  • IndustryARC
Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, joint pain, and temporary loss of cognitive ability. Immune response is directed toward the body’s own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the age group of 25 to 45. Although the main cause of disease is unknown, it is linked to genetic and hormonal factors. Globally increasing awareness about lupus is expected to remain key growth driver during the period of study.

Geographically, North America dominates the systemic lupus erythematosus market driven by best in class infrastructure, easy access to healthcare, higher awareness about the disease amongst citizens as well as practitioners, and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest markets for systemic lupus erythematosus market. Asia Pacific is projected to have fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, increased spending, and increasing awareness amongst population in developing nations such as China, and India in this region.

This report identifies the global systemic lupus erythematosus market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the systemic lupus erythematosus market.

This report segments the systemic lupus erythematosus market on the basis of therapies and regional market as follows:
Systemic Lupus Erythematosus Market research report is classified on the basis of therapies. Some of the major therapies covered in this report are as follows: Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the systemic lupus erythematosus market. Some of the major companies’ profiles in detail are as follows:

F. Hoffmann-la roche ltd
Glaxosmithkline plc (gsk)
Hadasit medical research services and development
Hansa medical ab
Harbor biosciences

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
1. Systemic Lupus Erythematosus Market – Overview

2. Executive Summary

3. Systemic Lupus Erythematosus Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Systemic Lupus Erythematosus Market– Forces
4.1. Drivers
4.2. Increasing awareness about SLE in emerging economies
4.3. Restraints
4.4. Opportunities
4.5. Challenges
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of New Entrants
4.6.4. Threat of Substitutes
4.6.5. Degree of Competition

5. Systemic Lupus Erythematosus Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Systemic Lupus Erythematosus Market, By Therapies
6.1. Antimalarial Drugs
6.2. Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
6.3. Corticosteroids Cytotoxic & Immunosuppressive Drugs
6.4. Biologics
6.5. Small Molecules

7. Systemic Lupus Erythematosus Market, By Geography
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW

8. Systemic Lupus Erythematosus Market – Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract

9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Anthera pharmaceuticals inc
9.2. Biotest ag
9.3. Biotica technology ltd.
9.4. Cephalon
9.5. Cornerstone therapeutics inc.
9.6. Creabilis therapeutics s.r.l.
9.7. Dynavax technologies
9.8. Eli lilly
9.9. F. Hoffmann-la roche ltd
9.10. Glaxosmithkline plc (gsk)
9.11. Hadasit medical research services and development
9.12. Hansa medical ab
9.13. Harbor biosciences
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Bibliography
10.5. Compilation of Expert Insights
10.6. Disclaimer
Note: Product cover images may vary from those shown